Surgery of high-grade gliomas guided by fluorescence: A retrospective study of 22 patients;Exérèse neurochirurgicale optimale des gliomes de haut grade guidée par fluorescence : Mise au point à partir d'une série rétrospective de 22 patients

Neurochirurgie

Volumn 59, Issue 1, 2013, Pages 9-16

  Jacquesson, T ^a   Ducray, F ^a   Maucort Boulch, D ^b   Armoiry, X ^c   Louis Tisserand, G ^a   Mbaye, M ^a   Pelissou Guyotat, I ^a   Guyotat, J ^a  

^a HÔPITAL NEUROLOGIQUE   (France)

^b CENTRE HOSPITALIER LYON SUD   (France)

^c HOSPICES CIVILS DE LYON   (France)

Author keywords

Aminolevulinic acid; Brain tumors; Fluorescence; Glioblastoma; Surgery; Survival analysis

Indexed keywords

ADULT; AGED; BRAIN SURGERY; CANCER GRADING; CANCER PROGNOSIS; CLINICAL ARTICLE; CLINICAL EXAMINATION; FEMALE; FLUORESCENCE ANALYSIS; FLUORESCENCE GUIDED SURGERY; GLIOBLASTOMA; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PATIENT MONITORING; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; REVIEW; SURGICAL TECHNIQUE;

AGED; AGED, 80 AND OVER; AMINOLEVULINIC ACID; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CLINICAL TRIALS, PHASE III AS TOPIC; COMBINED MODALITY THERAPY; CRANIAL IRRADIATION; DISEASE-FREE SURVIVAL; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MICROSCOPY, FLUORESCENCE; MICROSURGERY; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM, RESIDUAL; NEOVASCULARIZATION, PATHOLOGIC; NEURONAVIGATION; NEUROSURGICAL PROCEDURES; PROGNOSIS; PROTOPORPHYRINS; RETROSPECTIVE STUDIES; SURGERY, COMPUTER-ASSISTED;

EID: 84875370263     PISSN: 00283770     EISSN: 17730619     Source Type: Journal    
DOI: 10.1016/j.neuchi.2012.07.002     Document Type: Review

References (45)

1. Albert F.K., Forsting M., Sartor K., Adams H.P., Kunze S. Early postoperative magnetic resonance imaging after resection of malignant glioma: objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery 1994, 34(1):45-60.
2. Asthagiri A.R., Pouratian N., Sherman J., Ahmed G., Shaffrey M.E. Advances in brain tumor surgery. Neurol. Clin. 2007, 25(4):975-999.
3. Baldi I., Huchet A., Bauchet L., Loiseau H. Epidemiology of glioblastoma. Neurochirurgie 2010, 56(6):433-440.
4. Bauchet L., Rigau V., Mathieu-Daude H., Figarella-Branger D., Hugues D., Palusseau L., Bauchet F., Fabbro M., Campello C., Capelle L., Durand A., Tretarre B., Frappaz D., Henin D., Menei P., Honnorat J., Segnarbieux F. French brain tumor data bank: methodology and first results on 10,000 cases. J. Neurooncol. 2007, 84(2):189-199.
5. Chacko A.G., Kumar N.K., Chacko G., Athyal R., Rajshekhar V. Intraoperative ultrasound in determining the extent of resection of parenchymal brain tumours--a comparative study with computed tomography and histopathology. Acta Neurochir. (Wien) 2003, 145(9):743-748.
6. Collaud S., Juzeniene A., Moan J., Lange N. On the selectivity of 5-aminolevulinic acid-induced protoporphyrin IX formation. Curr. Med. Chem. Anticancer Agents 2004, 4(3):301-316.
7. Coluccia D., Fandino J., Fujioka M., Cordovi S., Muroi C., Landolt H. Intraoperative 5-aminolevulinic-acid-induced fluorescence in meningiomas. Acta Neurochir. (Wien) 2010, 152(10):1711-1719.
8. Daumas-Duport C., Meder J.F., Monsaingeon V., Missir O., Aubin M.L., Szikla G. Cerebral gliomas: malignancy, limits and spatial configuration. Comparative data from serial stereotaxic biopsies and computed tomography (a preliminary study based on 50 cases). J. Neuroradiol. 1983, 10(1):51-80.
9. Daumas-Duport C., Szikla G. Definition of limits and 3D configuration of cerebral gliomas. Histological data, therapeutic incidences. Neurochirurgie 1981, 27(5):273-284. (author's transl).
10. Devaux B.C., O'Fallon J.R., Kelly P.J. Resection, biopsy, and survival in malignant glial neoplasms. A retrospective study of clinical parameters, therapy, and outcome. J. Neurosurg. 1993, 78(5):767-775.
11. Diez V.R., Tejada S.S., Idoate Gastearena M.A., Garcia de E.R., Dominguez E.P., Aristu M.J. Surgery guided by 5-aminolevulinic fluorescence in glioblastoma: volumetric analysis of extent of resection in single-center experience. J. Neurooncol. 2011, 102(1):105-113.
12. Eleouet S., Rousset N., Carre J., Vonarx V., Vilatte C., Louet C., Lajat Y., Patrice T. Heterogeneity of delta-aminolevulinic acid-induced protoporphyrin IX fluorescence in human glioma cells and leukemic lymphocytes. Neurol. Res. 2000, 22(4):361-368.
13. Elia-Pasquet S., Provost D., Jaffre A., Loiseau H., Vital A., Kantor G., Maire J.P., Dautheribes M., Darrouzet V., Dartigues J.F., Brochard P., Baldi I. Incidence of central nervous system tumors in Gironde, France. Neuroepidemiology 2004, 23(3):110-117.
14. Feigl G.C., Ritz R., Moraes M., Klein J., Ramina K., Gharabaghi A., Krischek B., Danz S., Bornemann A., Liebsch M., Tatagiba M.S. Resection of malignant brain tumors in eloquent cortical areas: a new multimodal approach combining 5-aminolevulinic acid and intraoperative monitoring. J. Neurosurg. 2010, 113(2):352-357.
15. Hatiboglu M.A., Weinberg J.S., Suki D., Rao G., Prabhu S.S., Shah K., Jackson E., Sawaya R. Impact of intraoperative high-field magnetic resonance imaging guidance on glioma surgery: a prospective volumetric analysis. Neurosurgery 2009, 64(6):1073-1081.
16. Hottinger A.F., Stupp R. Therapeutic strategies for the management of gliomas. Rev. Neurol. (Paris) 2008, 164(6-7):523-530.
17. Idoate M.A., Diez V.R., Echeveste J., Tejada S. Pathological characterization of the glioblastoma border as shown during surgery using 5-aminolevulinic acid-induced fluorescence. Neuropathology 2011, 31(6):575-582.
18. Lacroix M., bi-Said D., Fourney D.R., Gokaslan Z.L., Shi W., DeMonte F., Lang F.F., McCutcheon I.E., Hassenbusch S.J., Holland E., Hess K., Michael C., Miller D., Sawaya R. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J. Neurosurg. 2001, 95(2):190-198.
19. Laws E.R., Parney I.F., Huang W., Anderson F., Morris A.M., Asher A., Lillehei K.O., Bernstein M., Brem H., Sloan A., Berger M.S., Chang S. Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. J. Neurosurg. 2003, 99(3):467-473.
20. Nabavi A., Thurm H., Zountsas B., Pietsch T., Lanfermann H., Pichlmeier U., Mehdorn M. Five-aminolevulinic acid for fluorescence-guided resection of recurrent malignant gliomas: a phase II study. Neurosurgery 2009, 65(6):1070-1076.
21. Psimaras D., Delattre J.Y. Perspectives in diagnosis and management of malignant gliomas. Cancer Radiother. 2008, 12(6-7):695-700.
22. Roberts D.W., Valdes P.A., Harris B.T., Fontaine K.M., Hartov A., Fan X., Ji S., Lollis S.S., Pogue B.W., Leblond F., Tosteson T.D., Wilson B.C., Paulsen K.D. Coregiste-red fluorescence-enhanced tumor resection of malignant glioma: relationships between delta-aminolevulinic acid-induced protoporphyrin IX fluorescence, magnetic resonance imaging enhancement, and neuropathological parameters. J. Neurosurg. 2011, 114(3):595-603.
23. Rygh O.M., Selbekk T., Torp S.H., Lydersen S., Hernes T.A., Unsgaard G. Comparison of navigated 3D ultrasound findings with histopathology in subsequent phases of glioblastoma resection. Acta Neurochir. (Wien) 2008, 150(10):1033-1041.
24. Sailer R., Strauss W.S., Wagner M., Emmert H., Schneckenburger H. Relation between intracellular location and photodynamic efficacy of 5-aminolevulinic acid-induced protoporphyrin IX in vitro. Comparison between human glioblastoma cells and other cancer cell lines. Photochem. Photobiol. Sci. 2007, 6(2):145-151.
25. Sanai N., Berger M.S. Glioma extent of resection and its impact on patient outcome. Neurosurgery 2008, 62(4):753-764.
26. Sanai N., Polley M.Y., McDermott M.W., Parsa A.T., Berger M.S. An extent of resection threshold for newly diagnosed glioblastomas. J. Neurosurg. 2011, 115(1):3-8.
27. Senft C., Seifert V., Hermann E., Franz K., Gasser T. Usefulness of intraoperative ultra low-field magnetic resonance imaging in glioma surgery. Neurosurgery 2008, 63(4 Suppl. 2):257-266.
28. Simpson J.R., Horton J., Scott C., Curran W.J., Rubin P., Fischbach J., Isaacson S., Rotman M., Asbell S.O., Nelson J.S. Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. Int. J. Radiat. Oncol. Biol. Phys. 1993, 26(2):239-244.
29. Stummer W., Novotny A., Stepp H., Goetz C., Bise K., Reulen H.J. Fluorescence-guided resection of glioblastoma multiforme by using 5-aminolevulinic acid-induced porphyrins: a prospective study in 52 consecutive patients. J. Neurosurg. 2000, 93(6):1003-1013.
30. Stummer W., Pichlmeier U., Meinel T., Wiestler O.D., Zanella F., Reulen H.J. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol. 2006, 7(5):392-401.
31. Stummer W., Reulen H.J., Meinel T., Pichlmeier U., Schumacher W., Tonn J.C., Rohde V., Oppel F., Turowski B., Woiciechowsky C., Franz K., Pietsch T. Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery 2008, 62(3):564-576.
32. Stummer W., Stocker S., Wagner S., Stepp H., Fritsch C., Goetz C., Goetz A.E., Kiefmann R., Reulen H.J. Intraoperative detection of malignant gliomas by 5-aminolevulinic acid-induced porphyrin fluorescence. Neurosurgery 1998, 42(3):518-525.
33. Stummer W., Tonn J.C., Mehdorn H.M., Nestler U., Franz K., Goetz C., Bink A., Pichlmeier U. Counterbalancing risks and gains from extended resections in malignant glioma surgery: a supplemental analysis from the randomized 5-aminolevulinic acid glioma resection study. J. Neurosurg. 2011, 114(3):613-623.
34. Stupp R., Hegi M.E., Mason W.P., van den Bent M.J., Taphoorn M.J., Janzer R.C., Ludwin S.K., Allgeier A., Fisher B., Belanger K., Hau P., Brandes A.A., Gijtenbeek J., Marosi C., Vecht C.J., Mokhtari K., Wesseling P., Villa S., Eisenhauer E., Gorlia T., Weller M., Lacombe D., Cairncross J.G., Mirimanoff R.O. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009, 10(5):459-466.
35. Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J., Belanger K., Brandes A.A., Marosi C., Bogdahn U., Curschmann J., Janzer R.C., Ludwin S.K., Gorlia T., Allgeier A., Lacombe D., Cairncross J.G., Eisenhauer E., Mirimanoff R.O. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 2005, 352(10):987-996.
36. Tonn J.C., Stummer W. Fluorescence-guided resection of malignant gliomas using 5-aminolevulinic acid: practical use, risks, and pitfalls. Clin. Neurosurg. 2008, 55:20-26.
37. Unsgaard G., Ommedal S., Muller T., Gronningsaeter A., Nagelhus Hernes T.A. Neuronavigation by intraoperative three-dimensional ultrasound: initial experience during brain tumor resection. Neurosurgery 2002, 50(4):804-812.
38. Unsgaard G., Selbekk T., Brostrup M.T., Ommedal S., Torp S.H., Myhr G., Bang J., Nagelhus Hernes T.A. Ability of navigated 3D ultrasound to delineate gliomas and metastases--comparison of image interpretations with histopathology. Acta Neurochir. (Wien) 2005, 147(12):1259-1269.
39. Valdes P.A., Leblond F., Kim A., Harris B.T., Wilson B.C., Fan X., Tosteson T.D., Hartov A., Ji S., Erkmen K., Simmons N.E., Paulsen K.D., Roberts D.W. Quantitative fluorescence in intracranial tumor: implications for ALA-induced PpIX as an intraoperative biomarker. J. Neurosurg. 2011, 115(1):11-17.
40. van den Bent M.J., Grisold W., Frappaz D., Stupp R., Desir J.P., Lesimple T., Dittrich C., de Jonge M.J., Brandes A., Frenay M., Carpentier A.F., Chollet P., Oliveira J., Baron B., Lacombe D., Schuessler M., Fumoleau P. European Organization for Research and Treatment of Cancer (EORTC) open label phase II study on glufosfamide administered as a 60-minute infusion every 3 weeks in recurrent glioblastoma multiforme. Ann. Oncol. 2003, 14(12):1732-1734.
41. van den Bent M.J., Hegi M.E., Stupp R. Recent developments in the use of chemotherapy in brain tumours. Eur. J. Cancer. 2006, 42(5):582-588.
42. Vecht C.J., Avezaat C.J., van Putten W.L., Eijkenboom W.M., Stefanko S.Z. The influence of the extent of surgery on the neurological function and survival in malignant glioma. A retrospective analysis in 243 patients. J. Neurol. Neurosurg. Psychiatry 1990, 53(6):466-471.
43. Wen P.Y., Kesari S. Malignant gliomas in adults. N. Engl. J. Med. 2008, 359(5):492-507.
44. Willems P.W., Taphoorn M.J., Burger H., Berkelbach van der Sprenkel J.W., Tulleken C.A. Effectiveness of neuronavigation in resecting solitary intracerebral contrast-enhancing tumors: a randomized controlled trial. J. Neurosurg. 2006, 104(3):360-368.
45. Willems P.W., van der Sprenkel J.W., Tulleken C.A., Viergever M.A., Taphoorn M.J. Neuronavigation and surgery of intracerebral tumours. J. Neurol. 2006, 253(9):1123-1136.